Cipla Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 5/6

Cipla verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 19.7%, während die Gewinne der Branche Pharmaceuticals jährlich um gewachsen und zwar um 13.4%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 9.2%. Die Eigenkapitalrendite von Cipla beträgt 15.7% und die Nettomargen betragen 17%.

Wichtige Informationen

19.7%

Wachstumsrate der Gewinne

19.7%

EPS-Wachstumsrate

Pharmaceuticals Wachstum der Industrie	17.5%
Wachstumsrate der Einnahmen	9.2%
Eigenkapitalrendite	15.7%
Netto-Marge	17.0%
Letzte Ertragsaktualisierung	30 Sep 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Cipla Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Nov 01

Earnings Update: Cipla Limited (NSE:CIPLA) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

May 14

With EPS Growth And More, Cipla (NSE:CIPLA) Makes An Interesting Case

May 03

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Feb 14

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Jan 26

Getting In Cheap On Cipla Limited (NSE:CIPLA) Is Unlikely

Jan 08

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Nov 15

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Oct 05

Does Cipla (NSE:CIPLA) Have A Healthy Balance Sheet?

Aug 04

Is Cipla (NSE:CIPLA) A Risky Investment?

Mar 24

A Look At The Fair Value Of Cipla Limited (NSE:CIPLA)

Mar 06

Cipla (NSE:CIPLA) Has A Pretty Healthy Balance Sheet

Dec 11

Estimating The Fair Value Of Cipla Limited (NSE:CIPLA)

Aug 19

Cipla (NSE:CIPLA) Will Pay A Dividend Of ₹5.00

Jul 30

Cipla (NSE:CIPLA) Could Easily Take On More Debt

Jul 14

If EPS Growth Is Important To You, Cipla (NSE:CIPLA) Presents An Opportunity

Jul 01

Cipla Limited (NSE:CIPLA) Shares Could Be 34% Above Their Intrinsic Value Estimate

Apr 30

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Mar 23

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Dec 18

Aufschlüsselung der Einnahmen und Ausgaben

Wie Cipla Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NSEI:CIPLA Einnahmen, Ausgaben und Erträge (INR Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
30 Sep 24	262,642	44,751	57,345	0
30 Jun 24	258,922	43,035	56,178	0
31 Mar 24	255,367	41,216	54,901	0
31 Dec 23	251,163	37,082	53,757	0
30 Sep 23	243,407	34,532	52,563	0
30 Jun 23	235,108	31,112	51,260	0
31 Mar 23	225,593	28,019	50,151	0
31 Dec 22	222,187	26,383	48,947	0
30 Sep 22	218,874	25,660	48,184	0
30 Jun 22	216,105	24,884	35,984	0
31 Mar 22	217,078	25,168	46,669	0
31 Dec 21	210,718	25,681	43,285	0
30 Sep 21	207,616	25,876	43,004	0
30 Jun 21	202,801	25,417	42,435	0
31 Mar 21	191,205	24,049	41,281	0
31 Dec 20	188,779	22,374	40,432	0
30 Sep 20	180,802	18,403	39,444	0
30 Jun 20	174,377	16,462	38,851	0
31 Mar 20	170,805	15,465	38,694	0
31 Dec 19	171,206	16,678	38,608	0
30 Sep 19	167,572	16,489	38,331	0
30 Jun 19	163,733	15,546	37,837	0
31 Mar 19	163,232	15,277	37,415	0
31 Dec 18	155,224	13,391	35,683	0
30 Sep 18	154,287	14,074	35,078	0
30 Jun 18	154,992	14,530	34,564	0
31 Mar 18	151,053	14,105	34,151	0
31 Dec 17	147,618	11,701	32,973	0
30 Sep 17	144,951	11,444	32,730	0
30 Jun 17	141,637	10,762	32,875	0
31 Mar 17	143,340	10,064	33,011	0
31 Dec 16	142,509	11,213	31,554	0
30 Sep 16	137,547	10,071	31,012	0
30 Jun 16	134,335	12,219	30,089	0
31 Mar 16	135,480	13,600	29,258	0
31 Dec 15	135,044	16,847	39,028	1,120
30 Sep 15	131,633	16,694	38,220	1,120
30 Jun 15	124,782	15,368	37,096	1,120
31 Mar 15	113,454	11,808	23,549	0
31 Dec 14	106,195	11,818	32,156	1,058
30 Sep 14	105,627	11,383	31,333	1,058
30 Jun 14	104,164	11,976	30,224	1,058
31 Mar 14	101,734	13,884	29,546	1,058
31 Dec 13	94,330	14,042	25,122	432

Qualität der Erträge: CIPLA hat hohe Qualitätseinkünfte.

Wachsende Gewinnspanne: CIPLADie aktuellen Gewinnspannen (17%) sind höher als im letzten Jahr (14.2%).

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: CIPLAIn den letzten 5 Jahren sind die Gewinne von 19.7% jährlich gestiegen.

Beschleunigtes Wachstum: CIPLADas Gewinnwachstum des Unternehmens im letzten Jahr (29.6%) übertrifft seinen 5-Jahres-Durchschnitt (19.7% pro Jahr).

Erträge im Vergleich zur Industrie: CIPLA Das Gewinnwachstum im vergangenen Jahr (29.6%) übertraf das der Branche Pharmaceuticals 20% .

Eigenkapitalrendite

Hohe Eigenkapitalrendite: CIPLADie Eigenkapitalrendite des Unternehmens (15.7%) wird als niedrig angesehen.

Cipla Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Second quarter 2025 earnings: EPS exceeds analyst expectations

Cipla Limited to Report Q2, 2025 Results on Oct 29, 2024

Cipla Limited to Report Q1, 2025 Results on Jul 26, 2024

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Cipla Limited to Report Q4, 2024 Results on May 10, 2024

Third quarter 2024 earnings: EPS exceeds analyst expectations

Recent updates

Cipla Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Second quarter 2025 earnings: EPS exceeds analyst expectations

Cipla, Alkem Laboratories Reportedly in Final Lap to Buy SMT

Cipla Limited Announces Executive Appointments

Cipla Limited to Report Q2, 2025 Results on Oct 29, 2024

Cipla Limited's (NSE:CIPLA) Share Price Could Signal Some Risk

Cipla Limited Announces Resignation of M K Hamied as Vice Chairman and Non-Executive Director, Effective October 29, 2024

Cipla Limited Announces Retirement of S. Radhakrishnan, Non-Executive Director

Cipla Limited to Report Q1, 2025 Results on Jul 26, 2024

Cipla (NSE:CIPLA) Is Increasing Its Dividend To ₹13.00

Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA

Cipla's (NSE:CIPLA) Upcoming Dividend Will Be Larger Than Last Year's

Cipla Limited Approves the Appointment of Dr. Balram Bhargava as an Independent Director

Promoter Group Entities Reportedly Likely to Sell 2.5% Stake in Cipla worth INR 26.37 Billion via Block Deals

Earnings Update: Cipla Limited (NSE:CIPLA) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Dividend increased to ₹13.00

Cipla Limited, Annual General Meeting, Aug 20, 2024

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Cipla Limited Announces Retirement of S. Radhakrishnan as Non-Executive Director

With EPS Growth And More, Cipla (NSE:CIPLA) Makes An Interesting Case

Cipla Limited to Report Q4, 2024 Results on May 10, 2024

Cipla Limited Appoints Rajeev Kumar Sinha as Senior Management Personnel and Global Chief Manufacturing Officer, Effective April 1, 2024

Cipla Limited Appoints Venkata Sai Mungara as Senior Management Personnel and Global Head - Supply Chain, Effective from 1 April 2024

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Price target increased by 8.7% to ₹1,391

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Cipla Limited Announces Resignation of Ms. Samina Hamied as Executive Vice Chairperson

Third quarter 2024 earnings: EPS exceeds analyst expectations

Getting In Cheap On Cipla Limited (NSE:CIPLA) Is Unlikely

Is Cipla (NSE:CIPLA) Using Too Much Debt?

Second quarter 2024 earnings released: EPS: ₹14.01 (vs ₹9.78 in 2Q 2023)

Torrent Pharmaceuticals Reportedly Bid to Acquire the Stake of Cipla Stalled over Valuation Differences

Torrent Pharma Calls the Reports of Cipla Acquisition as Speculative

Family Rift Clouds $7 Billion Sale of Cipla

Cipla Limited to Report Q2, 2024 Results on Oct 27, 2023

Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?

Blackstone Reportedly Withdraws Plan to Acquire Founders' Stake in Cipla

Torrent Pharma Reportedly in Advance Talks with CVC Capital to Buyout Cipla Promoters

Cipla's Founding Family's Stake Sale Reportedly in Jeopardy over $13 Billion Valuation Target

Bain Capital Reportedly Approaches Dr. Reddy's Laboratories to Explore Joint Bid to Buy Out the Promoters of Cipla

Torrent Pharmaceutical Leads in the Race to Acquire Cipla

Torrent Reportedly in Top Gear to Close Out Cipla Buyout, in Talks with PES, Banks for Funds

Torrent Reportedly Joins Fray for Hamied Family Stake in Cipla

Blackstone Reportedly to Submit Bid for over 33% Stake in Cipla

Does Cipla (NSE:CIPLA) Have A Healthy Balance Sheet?

Cipla Promoters Reportedly Mull Stake Sale to Top PE Firms Blackstone, Baring Asia

Cipla Limited Announces Change in Management

Full year 2023 earnings: EPS misses analyst expectations

Cipla Limited, Annual General Meeting, Aug 10, 2023

Cipla Limited to Report Q1, 2024 Results on Jul 26, 2023

Shibam Group Holding Limited entered into a binding term sheet to acquire additional 51% stake in Saba Investment Ltd from Cipla Limited (NSEI:CIPLA) for $6.5 million.

Full year 2023 earnings: EPS misses analyst expectations

Cipla Limited Announces Resignation of Peter Mugyenyi as Independent Director, Effective May 13, 2023

Is Cipla (NSE:CIPLA) A Risky Investment?

A Look At The Fair Value Of Cipla Limited (NSE:CIPLA)

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Cipla Limited Announces the Launch of Cippoint

Cipla Limited to Report Q3, 2023 Results on Jan 25, 2023

Cipla (NSE:CIPLA) Has A Pretty Healthy Balance Sheet

Cipla Limited and Cipla Usa Inc. Announces the Launch of Leuprolide Acetate Injection Depot 22.5Mg

Price target increased to ₹1,208

Price target increased to ₹1,202

Second quarter 2023 earnings: EPS exceeds analyst expectations

Cipla Limited to Report Q2, 2023 Results on Nov 04, 2022

Cipla Limited Receives the Establishment Inspection Report Indicating Closure of the Inspection

Cipla Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Cipla Limited (NSEI:CIPLA) agreed to acquire additional 13.10% stake in Jiangsu Acebright Pharmaceutical Co. Limited for USD 16.40 million.

Estimating The Fair Value Of Cipla Limited (NSE:CIPLA)

Cipla Limited Announces Executive Changes